DeHeng Advised Haisen Pharma on Listing on the Main Board of SZSE

2023-04-11

On April 10, 2023, Zhejiang Haisen Pharmaceutical Co., Ltd. ("Haisen Pharma," stock code: 001367) was successfully listed on the main board of the Shenzhen Stock Exchange, and became one of the first listed enterprises after the introduction of the registration system to the SZSE main board. Haisen Pharma issued 17 million shares at the price of RMB 44.48 per share, and raised RMB 756,160,000, which will be mainly used for technological transformation projects of API production lines with an annual output of 200 tons of atorvastatin calcium, the construction of the R&D center and the multi-functional office building, and for replenishing the working capital.

As the issuer's legal counsel, the DeHeng team, with lawyers Ni Haizhong and Huang Junfu and Lou Mohan of its Hangzhou Office as signing lawyers, and support from lawyer Huang Luhao, paralegals Liu Xingyu and Wang Zian, worked closely and efficiently together and provided professional, efficient, high-quality whole-process legal services for the client.